Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy drug nivolumab tested for rare thymus cancers

NCT ID NCT03134118

Ongoing Disease control Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing the immunotherapy drug nivolumab in 55 patients with type B3 thymoma or thymic carcinoma that has worsened after platinum-based chemotherapy. The main goal is to see if nivolumab can stop the cancer from growing for at least 6 months. Researchers will also monitor side effects and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab (a type of immunotherapy drug that helps the immune system attack cancer cells)
What this could lead to
If successful, this could provide a new treatment option for patients with these rare thymus cancers that have progressed after chemotherapy.
What could go wrong
This is a small, early-phase trial with only 55 participants, so results may not apply broadly. Immunotherapy can cause serious immune-related side effects, and the cancer may still grow despite treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thymic carcinoma thymoma thymoma type B3

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYMIC CARCINOMA THYMOMA TYPE B3

Contacts and locations

Locations

  • Academisch Ziekenhuis Maastricht

    Maastricht, 6202, Netherlands

  • Assistance Publique - Hopitaux de Marseille - Hopital Nord (APHM)

    Marseille, France

  • CHU Toulouse - Hopital Larrey

    Toulouse, 31059, France

  • CHU de Brest

    Brest, 29200, France

  • CHU de Grenoble - La Tronche - Hôpital A. Michallon

    La Tronche, 38700, France

  • CHU de Lyon - Hopital Louis Pradel

    Bron, 69500, France

  • Centre Francois Baclesse

    Caen, 14076, France

  • Erasmus MC

    Rotterdam, Netherlands

  • Gustave Roussy

    Villejuif, 94805, France

  • Hospital Universitario 12 De Octubre

    Madrid, Spain

  • Institut Curie- Hopital de Paris

    Paris, 75248, France

  • Institut Jules Bordet

    Brussels, Belgium

  • NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital

    Glasgow, United Kingdom

  • Royal Marsden Hospital - Chelsea, London

    London, United Kingdom

  • Royal Marsden Hospital - Sutton, Surrey

    Sutton, United Kingdom

  • The Christie NHS Foundation Trust

    Wythenshawe, M23 9LT, United Kingdom

  • The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

    Amsterdam, 1066, Netherlands

  • UniversitaetsSpital Zurich

    Zurich, Switzerland

  • Universitair Ziekenhuis Antwerpen (UZA)

    Edegem, Belgium

  • Vall d'Hebron Institut d'Oncologia

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.